Hologic Reports $1,047.8 Million Revenue with 2.5% Growth, Net Income Declines

Hologic, Inc. reported a revenue of $1,047.8 million for the three months ended December 27, 2025, marking a 2.5% increase from $1,021.8 million in the same period last year. The growth was driven by a rise in product revenues, which reached $831.4 million, up from $817.9 million, and service revenues, which increased to $216.4 million from $203.9 million. However, net income decreased to $179.1 million, or $0.79 per diluted share, compared to $201.0 million, or $0.87 per diluted share, in the prior year, reflecting a decline in profitability.

The company experienced notable changes in its operational metrics. Product revenues from the GYN Surgical segment increased by 8.0% to $177.4 million, largely due to the acquisition of Gynesonics, which contributed $9.1 million. Skeletal Health revenues surged by 124.3% to $15.7 million, attributed to increased sales of Horizon DXA systems. Conversely, Diagnostics revenues fell by 0.8% to $433.2 million, primarily due to decreased sales of molecular diagnostic assays, particularly related to COVID-19 testing. Breast Health revenues also declined by 2.2% to $205.1 million, impacted by longer sales cycles and a stop-ship of certain products.

In terms of strategic developments, Hologic announced a definitive agreement on October 21, 2025, to be acquired by funds managed by Blackstone Inc. and TPG Capital for $76.00 per share in cash, with potential additional payments based on future performance metrics. This transaction is expected to close in the first half of 2026, pending stockholder and regulatory approvals. The company also completed the acquisition of Gynesonics in January 2025, enhancing its GYN Surgical portfolio.

Operationally, Hologic's cash and cash equivalents increased to $2,168.0 million as of December 27, 2025, up from $1,959.5 million at the end of the previous quarter. The company reported net cash provided by operating activities of $229.9 million, driven by strong cash generation from its core operations. However, the company also noted a decrease in accounts receivable, indicating improved collection efforts. Looking ahead, Hologic anticipates continued focus on integrating acquisitions and expanding its product offerings, while navigating the complexities of the healthcare market and regulatory environment.